Use of biperiden hydrochloride in a child with severe dyskinesia induced by phenytoin

Hüseyin Caksen1, Dursun Odabaş, Omer Anlar

  • 1Department of Pediatrics, Yüzüncü Yil University Faculty of Medicine, Van, Turkey. huseyincaksen@hotmail.com

Insights

Phenytoin, an epilepsy medication, can cause severe involuntary movements (dyskinesia) in children. Biperiden effectively treated these drug-induced movement disorders, offering a potential solution for this adverse effect.

Area of Science:

  • Neurology
  • Pharmacology

Background:

  • Epilepsy management often involves antiepileptic drugs.
  • Phenytoin is a commonly prescribed anticonvulsant medication.

Observation:

  • A 5-year-old girl developed speech disorder and gait abnormalities after starting phenytoin.
  • Physical examination revealed severe extrapyramidal movements, slurred speech, and ataxic gait.
  • The patient exhibited repetitive scalp scratching.

Findings:

  • Serum phenytoin levels were within the normal therapeutic range.
  • Discontinuation of phenytoin and initiation of biperiden led to a marked decrease and near-complete resolution of abnormal movements.
  • Electroencephalography showed diffuse slow waves, and brain MRI was normal.

Implications:

  • Severe dyskinesia is a potential adverse effect of phenytoin therapy, even within therapeutic serum levels.
  • Biperiden is an effective treatment for phenytoin-induced dyskinesia.
  • This case highlights the importance of recognizing and managing drug-induced movement disorders in pediatric patients.

Related Concept Videos

Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Parkinson's Disease: Treatment01:24

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...